SG11201505431XA - Therapeutic compositions and methods involving mrna transfection - Google Patents

Therapeutic compositions and methods involving mrna transfection

Info

Publication number
SG11201505431XA
SG11201505431XA SG11201505431XA SG11201505431XA SG11201505431XA SG 11201505431X A SG11201505431X A SG 11201505431XA SG 11201505431X A SG11201505431X A SG 11201505431XA SG 11201505431X A SG11201505431X A SG 11201505431XA SG 11201505431X A SG11201505431X A SG 11201505431XA
Authority
SG
Singapore
Prior art keywords
therapeutic compositions
methods involving
mrna transfection
involving mrna
transfection
Prior art date
Application number
SG11201505431XA
Other languages
English (en)
Inventor
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Original Assignee
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark C Herzberg, Karen Farnie Ross, Brent S Sorenson filed Critical Mark C Herzberg
Publication of SG11201505431XA publication Critical patent/SG11201505431XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201505431XA 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection SG11201505431XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Publications (1)

Publication Number Publication Date
SG11201505431XA true SG11201505431XA (en) 2015-08-28

Family

ID=51167392

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505431XA SG11201505431XA (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection
SG10201603946PA SG10201603946PA (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201603946PA SG10201603946PA (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Country Status (13)

Country Link
US (3) US20150344537A1 (zh)
EP (2) EP3501551B1 (zh)
JP (4) JP2016511230A (zh)
KR (2) KR102056511B1 (zh)
CN (1) CN105473163A (zh)
AU (1) AU2014205298B2 (zh)
CA (2) CA3152721A1 (zh)
ES (1) ES2738315T3 (zh)
IL (2) IL239898B (zh)
NZ (1) NZ710495A (zh)
PL (1) PL2943226T3 (zh)
SG (2) SG11201505431XA (zh)
WO (1) WO2014110366A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710495A (en) * 2013-01-11 2019-10-25 Mark C Herzberg Therapeutic compositions and methods involving mrna transfection
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US20070123455A1 (en) * 2003-04-04 2007-05-31 Joel Palefsky Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
WO2012135805A2 (en) * 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
WO2012145680A2 (en) * 2011-04-21 2012-10-26 George Mason Intellectual Properties, Inc. Anti-microbial peptides and uses therefore
NZ710495A (en) * 2013-01-11 2019-10-25 Mark C Herzberg Therapeutic compositions and methods involving mrna transfection

Also Published As

Publication number Publication date
US20200231640A1 (en) 2020-07-23
US20240166701A1 (en) 2024-05-23
NZ710495A (en) 2019-10-25
EP2943226B1 (en) 2019-03-13
CA2901409A1 (en) 2014-07-17
IL262252B (en) 2020-06-30
AU2014205298B2 (en) 2018-11-01
CA2901409C (en) 2022-06-07
EP3501551A1 (en) 2019-06-26
JP6956059B2 (ja) 2021-10-27
KR20160031999A (ko) 2016-03-23
PL2943226T3 (pl) 2019-09-30
IL262252A (en) 2018-11-29
IL239898B (en) 2018-10-31
CA3152721A1 (en) 2014-07-17
JP2016511230A (ja) 2016-04-14
AU2014205298A1 (en) 2015-08-13
JP2019031521A (ja) 2019-02-28
KR20180026811A (ko) 2018-03-13
CN105473163A (zh) 2016-04-06
US11912744B2 (en) 2024-02-27
EP3501551B1 (en) 2023-06-07
JP2021019644A (ja) 2021-02-18
KR102119985B1 (ko) 2020-06-05
ES2738315T3 (es) 2020-01-21
JP6473729B2 (ja) 2019-02-20
EP3501551C0 (en) 2023-06-07
IL239898A0 (en) 2015-08-31
WO2014110366A1 (en) 2014-07-17
EP2943226A4 (en) 2016-11-23
SG10201603946PA (en) 2016-07-28
EP2943226A1 (en) 2015-11-18
US20150344537A1 (en) 2015-12-03
JP2017052781A (ja) 2017-03-16
KR102056511B1 (ko) 2019-12-16

Similar Documents

Publication Publication Date Title
IL285985B1 (en) Therapeutic nuclease preparations and methods
HK1226301A1 (zh) 修飾的治療劑及其組合物
HK1222122A1 (zh) 選擇性藥物遞送組合物及使用方法
IL286759A (en) Therapeutic methods and preparations
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
EP2953474A4 (en) COMPOSITIONS AND METHODS
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
IL262252B (en) Medicinal compositions and processes involving mRNA transfection
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
HK1220920A1 (zh) 治療性組合物和其用途
EP2999474A4 (en) THERAPEUTIC AND METHOD OF USE
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HK1217720A1 (zh) 選擇性遞送分子及使用方法
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
HK1224307A1 (zh) 原毒素- 變體及其使用方法
EP2806894A4 (en) METHODS AND COMPOSITIONS FOR THERAPEUTICS
HK1217432A1 (zh) 多核苷酸轉染組合物和方法
EP2961386A4 (en) MIARN PROFILING COMPOSITIONS AND METHODS OF USE
EP2983789A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
IL245529A0 (en) Rapidly disintegrating formulations and methods of use
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
IL244537A0 (en) New administration preparations and methods of their use
GB201319255D0 (en) Therapeutic compositions and methods